Plant polyphenols in the treatment of age-associated diseases: Revealing the pleiotropic effects of icariin by network analysis

Molecular Nutrition and Food Research

Volumn 58, Issue 1, 2014, Pages 49-60

  Schluesener, Jan Kevin ^a   Schluesener, Hermann ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alzheimer; Network; Osteoporosis; Toxicogenomics; Traditional Chinese Medicine (TCM)

Indexed keywords

FLAVONOID; ICARIIN; NITRIC OXIDE SYNTHASE; PDE5A PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHODIESTERASE V; POLYPHENOL; SIRT1 PROTEIN, HUMAN; SIRTUIN 1;

AGING; ALZHEIMER; CARDIOMYOPATHY; DEGENERATIVE DISEASE; GENE EXPRESSION; GENETICS; HUMAN; INFLAMMATION; LIVER DISEASE; METABOLISM; MUSCLE DISEASE; NETWORK; OSTEOPOROSIS; REVIEW; TOXICOGENOMICS; TRADITIONAL CHINESE MEDICINE (TCM);

ALZHEIMER; NETWORK; OSTEOPOROSIS; TOXICOGENOMICS; TRADITIONAL CHINESE MEDICINE (TCM);

AGING; CARDIOMYOPATHIES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FLAVONOIDS; GENE EXPRESSION; HUMANS; INFLAMMATION; LIVER DISEASES; MUSCULAR DISEASES; NEURODEGENERATIVE DISEASES; NITRIC OXIDE SYNTHASE; OSTEOPOROSIS; POLYPHENOLS; PPAR ALPHA; SIRTUIN 1;

EID: 84891433544     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201300409     Document Type: Review

References (160)

1. Ebrahimi, A., Schluesener, H. J., Natural polyphenols against neurodegenerative disorders: potentials and pitfalls. Age. Res. Rev. 2012, 11, 329-345.
2. Mandel, S. A., Amit, T., Weinreb, O., Youdim, M. B. H., Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J. Alzheimers Dis. 2011, 25, 187-208.
3. Craggs, L., Kalaria, R. N., Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport 2011, 22, 1-3.
4. Wojcik, M., Burzynska-Pedziwiatr, I., Wozniak, L. A., A review of natural and synthetic antioxidants important for health and longevity. Curr. Med. Chem. 2010, 17, 3262-3288.
5. Knauf, C., Rieusset, J., Foretz, M., Cani, P. D. et al., Peroxisome proliferator-activated receptor-alpha-null mice have increased white adipose tissue glucose utilization, GLUT4, and fat mass: role in liver and brain. Endocrinology 2006, 147, 4067-4078.
6. King, B. L., Davis, A. P., Rosenstein, M. C., Wiegers, T. C. et al., Ranking transitive chemical-disease inferences using local network topology in the comparative toxicogenomics database. PLoS One 2012, 7, e46524.
7. Bollen, E., Prickaerts, J., Phosphodiesterases in neurodegenerative disorders. IUBMB Life 2012, 64, 965-970.
8. García-Osta, A., Cuadrado-Tejedor, M., García-Barroso, C., Oyarzábal, J. et al., Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem. Neurosci. 2012, 3, 832-844.
9. Cheng, Y.-F., Wang, C., Lin, H.-B., Li, Y.-F. et al., Inhibition of phosphodiesterase-4 reverses memory deficits produced by Aβ25-35 or Aβ1-40 peptide in rats. Psychopharmacology (Berl.) 2010, 212, 181-191.
10. Xin, Z. C., Kim, E., Lin, C., Liu, W. et al., Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J. Androl. 2003, 5, 15-18.
11. Liu, W.-J., Xin, Z.-C., Xin, H., Yuan, Y.-M. et al., Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J. Androl. 2005, 7, 381-388.
12. Ning, H., Xin, Z.-C., Lin, G., Banie, L. et al., Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology 2006, 68, 1350-1354.
13. Zhou, F., Xin, H., Liu, T., Li, G. Y. et al., Effects of icariside II on improving erectile function in rats with streptozotocin-induced diabetes. J. Androl. 2012, 33, 832-844.
14. Tanaka, Y., Tanaka, R., Liu, M., Hattori, N. et al., Cilostazol attenuates ischemic brain injury and enhances neurogenesis in the subventricular zone of adult mice after transient focal cerebral ischemia. Neuroscience 2010, 171, 1367-1376.
15. Zhang, R., Wang, Y., Zhang, L., Zhang, Z. et al., Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002, 33, 2675-2680.
16. Zhang, L., Zhang, R. L., Wang, Y., Zhang, C. et al., Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 2005, 36, 847-852.
17. Xie, J., Shen, L., Yang, Y.-P., Zhou, P.-Q. et al., Prevention action of Chinese herbs for tonifying kidney on bone loss in senile males: 1 year follow-up. Chin. J. Clin. Rehabil. 2004, 4, 5180-5181. [Available: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/700/CN-00516700/frame.html.]
18. Zhang, G., Qin, L., Shi, Y., Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. J. Bone Miner. Res. 2007, 22, 1072-1079.
19. Dell'Agli, M., Galli, G. V., Dal Cero, E., Belluti, F. et al., Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J. Nat. Prod. 2008, 71, 1513-1517.
20. Nie, J., Luo, Y., Huang, X.-N., Gong, Q.-H. et al., Icariin inhibits beta-amyloid peptide segment 25-35 induced expression of beta-secretase in rat hippocampus. Eur. J. Pharmacol. 2010, 626, 213-218.
21. Zeng, K.-W., Ko, H., Yang, H. O., Wang, X.-M., Icariin attenuates β-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 2010, 59, 542-550.
22. Urano, T., Tohda, C., Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β-induced neurite atrophy. Phytother. Res. 2010, 24, 1658-1663.
23. Wu, B., Chen, Y., Huang, J., Ning, Y. et al., Icariin improves cognitive deficits and activates quiescent neural stem cells in aging rats. J. Ethnopharmacol. 2012, 142, 746-753.
24. Li, F., Gong, Q.-H., Wu, Q., Lu, Y.-F., Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacol. Biochem. Behav. 2010, 96, 301-305. [Available: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20566405&retmode=ref&cmd=prlinks]
25. Luo, Y., Nie, J., Gong, Q.-H., Lu, Y.-F. et al., Protective effects of icariin against learning and memory deficits induced by aluminium in rats. Clin. Exp. Pharmacol. Physiol. 2007, 34, 792-795.
26. He, X.-L., Zhou, W.-Q., Bi, M.-G., Du, G.-H., Neuroprotective effects of icariin on memory impairment and neurochemical deficits in senescence-accelerated mouse prone 8 (SAMP8) mice. Brain Res. 2010, 1334, 73-83.
27. Pan, Y., Kong, L., Xia, X., Zhang, W. et al., Antidepressant-like effect of icariin and its possible mechanism in mice. Pharmacol. Biochem. Behav. 2005, 82, 686-694.
28. Zhu, H.-R., Wang, Z.-Y., Zhu, X.-L., Wu, X.-X. et al., Icariin protects against brain injury by enhancing SIRT1-dependent PGC-1alpha expression in experimental stroke. Neuropharmacology 2010, 59, 70-76.
29. Xu, R.-X., Wu, Q., Luo, Y., Gong, Q.-H. et al., Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats. Clin. Exp. Pharmacol. Physiol. 2009, 36, 810-815.
30. Sha, D., Li, L., Ye, L., Liu, R. et al., Icariin inhibits neurotoxicity of beta-amyloid by upregulating cocaine-regulated and amphetamine-regulated transcripts. Neuroreport 2009, 20, 1564-1567.
31. Chaki, S., Kawashima, N., Suzuki, Y., Shimazaki, T. et al., Cocaine- and amphetamine-regulated transcript peptide produces anxiety-like behavior in rodents. Eur. J. Pharmacol. 2003, 464, 49-54.
32. James, M. H., Charnley, J. L., Jones, E., Levi, E. M. et al., Cocaine-and amphetamine-regulated transcript (CART) signaling within the paraventricular thalamus modulates cocaine-seeking behaviour. PLoS One 2010, 5, e12980. doi:10.1371/journal.pone.0012980.
33. Rubio-Perez, J. M., Morillas-Ruiz, J. M., A review: inflammatory process in Alzheimer's disease, role of cytokines. Scientif. World J. 2012, 2012, 756357. doi: 10.1100/2012/756357.
34. Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., A meta-analysis of cytokines in Alzheimer's disease. Biologic. Psyhiatr. 2010, 68, 930-941.
35. Hamel, E., Nicolakakis, N., Aboulkassim, T., Ongali, B. et al., Oxidative stress and cerebrovascular dysfunction in mouse models of Alzheimer's disease. Exp. Physiol. 2008, 93, 116-120.
36. Wu, J., Du, J., Xu, C., Le, J. et al., In vivo and in vitro anti-inflammatory effects of a novel derivative of icariin. Immunopharmacol. Immunotoxicol. 2011, 33, 49-54.
37. Schipper, H., Gupta, A., Szarek, W., Suppression of glial HO-1 activity as a potential neurotherapeutic intervention in AD. Curr. Alzheimer Res. 2009, 6, 424-430.
38. Cuadrado, A., Rojo, A. I., Heme oxygenase-1 as a therapeutic target in neurodegenerative diseases and brain infections. Curr. Pharm. Des. 2008, 14, 429-442.
39. Wu, J., Zhou, J., Chen, X., Fortenbery, N. et al., Attenuation of LPS-induced inflammation by ICT, a derivate of icariin, via inhibition of the CD14/TLR4 signaling pathway in human monocytes. Int. Immunopharmacol. 2012, 12, 74-79.
40. Zhou, J., Wu, J., Chen, X., Fortenbery, N. et al., Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions. Int. Immunopharmacol. 2011, 11, 890-898.
41. Richard, K. L., Filali, M., Préfontaine, P., Rivest, S., Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28, 5784-5793.
42. Guo, J., Li, F., Wu, Q., Gong, Q. et al., Protective effects of icariin on brain dysfunction induced by lipopolysaccharide in rats. Phytomedicine 2010, 17, 950-955.
43. Pan, Y., Wang, F.-M, Qiang, L.-Q., Zhang, D.-M. et al., Icariin attenuates chronic mild stress-induced dysregulation of the LHPA stress circuit in rats. Psychoneuroendocrinology 2010, 35, 272-283.
44. Li, L., Peng, L., Miao, J., Qiu, Y. et al., Icariin induces the expression of toll-like receptor 9 in ana-1 murine macrophages. Phytother. Res. 2011, 25, 1732-1735.
45. Hsieh, T.-P., Sheu, S.-Y., Sun, J.-S., Chen, M.-H. et al., Icariin isolated from Epimedium pubescens regulates osteoblasts anabolism through BMP-2, SMAD4, and Cbfa1 expression. Phytomedicine 2010, 17, 414-423.
46. Chen, K. M., Ma, H. P., Ge, B. F., Liu, X. Y. et al., Icariin enhances the osteogenic differentiation of bone marrow stromal cells but has no effects on the differentiation of newborn calvarial osteoblasts of rats. Pharmazie 2007, 62, 785-789.
47. Schakman, O., Kalista, S., Bertrand, L., Lause, P. et al., Role of Akt/GSK-3beta/beta-catenin transduction pathway in the muscle anti-atrophy action of insulin-like growth factor-I in glucocorticoid-treated rats. Endocrinology 2008, 149, 3900-3908.
48. Huang, F.-M., Lee, S.-S., Yang, S.-F., Chang, Y.-C., Up-regulation of receptor activator nuclear factor-kappaB ligand expression by root canal sealers in human osteoblastic cells. J. Endod. 2009, 35, 363-366.
49. Kang, H. K., Choi, Y.-H., Kwon, H., Lee, S.-B. et al., Estrogenic/antiestrogenic activities of a Epimedium koreanum extract and its major components: in vitro and in vivo studies. Food Chem. Toxicol. 2012, 50, 2751-2759.
50. Sheng, Z.-F., Xu, K., Ma, Y.-L., Liu, J.-H. et al., Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice. Osteoporos. Int. 2009, 20, 151-159.
51. Ye, H. Y., Lou, Y. J., Estrogenic effects of two derivatives of icariin on human breast cancer MCF-7 cells. Phytomedicine 2005, 12, 735-741.
52. Morony, S., Warmington, K., Adamu, S., Asuncion, F. et al., The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology 2005, 146, 3235-3243.
53. Kim, J. G., Kim, J. H., Kim, J. Y., Ku, S. Y. et al., Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 2007, 14, 913-918.
54. Rizzoli, R., Osteoporosis: non-hormonal treatment. Climacteric 2007, 10, 74-78.
55. Croucher, P. I., Shipman, C. M., Van Camp, B., Vanderkerken, K., Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003, 97, 818-824.
56. Wo, Y., Zhu, D.-Y., Yu, Y., Lou, Y., Involvement of NF-kappaB and AP-1 activation in icariin promoted cardiac differentiation of mouse embryonic stem cells. Eur. J. Pharmacol. 2008, 586, 59-66.
57. Ding, L., Liang, X.-G., Zhu, D.-Y., Lou, Y., Icariin promotes expression of PGC-1alpha, PPARalpha, and NRF-1 during cardiomyocyte differentiation of murine embryonic stem cells in vitro. Acta. Pharmacologica. Sinica. 2007, 28, 1541-1549.
58. Andrulionyte, L., Kuulasmaa, T., Chiasson, J.-L., Laakso, M. et al., Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 2007, 56, 1181-1186.
59. Jové, M., Salla, J., Planavila, A., Cabrero, A. et al., Impaired expression of NADH dehydrogenase subunit 1 and PPARgamma coactivator-1 in skeletal muscle of ZDF rats: restoration by troglitazone. J. Lipid. Res. 2004, 45, 113-123.
60. Kanie, N., Matsumoto, T., Kobayashi, T., Kamata, K., Relationship between peroxisome proliferator-activated receptors (PPAR alpha and PPAR gamma) and endothelium-dependent relaxation in streptozotocin-induced diabetic rats. Br. J. Pharmacol. 2003, 140, 23-32.
61. Memon, R. A., Tecott, L. H., Nonogaki, K., Beigneux, A. et al., Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 2000, 141, 4021-4031.
62. Nagothu, K. K., Bhatt, R., Kaushal, G. P., Portilla, D., Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int. 2005, 68, 2680-2693.
63. Cho, K.-H., Kim, H.-J., Kamanna, V. S., Vaziri, N. D., Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim. Biophys. Acta. 2010, 1800, 6-15.
64. Andrulionyte, L., Zacharova, J., Chiasson, J.-L., Laakso, M. et al., Common polymorphisms of the PPAR-gamma2 (Pro12Ala) and PGC-1alpha (Gly482Ser) genes are associated with the conversion from impaired glucose tolerance to type 2 diabetes in the STOP-NIDDM trial. Diabetologia 2004, 47, 2176-2184.
65. Tian, L., Xin, Z.-C., Liu, W.-J., Yang, Y.-M. et al., Effects of icariin on the erectile function and expression of nitrogen oxide synthase isoforms in corpus cavernosum of arterigenic erectile dysfunction rat model. Zhonghua Yi Xue Za Zhi 2004, 84, 954-957.
66. Xu, H.-B., Huang, Z.-Q., Vasorelaxant effects of icariin on isolated canine coronary artery. J. Cardiovasc. Pharmacol. 2007, 49, 207-213.
67. Xu, H.-B., Huang, Z.-Q., Icariin enhances endothelial nitric-oxide synthase expression on human endothelial cells in vitro. Vascul. Pharmacol. 2007, 47, 18-24.
68. Brotto, M., Abreu, E. L., Sarcopenia: pharmacology of today and tomorrow. J. Pharmacol. Exp. Ther. 2012, 343, 540-546.
69. Zhu, D.-Y., Lou, Y., Icariin-mediated expression of cardiac genes and modulation of nitric oxide signaling pathway during differentiation of mouse embryonic stem cells into cardiomyocytes in vitro1. Acta. Pharmacologica. Sinica. 2006, 27, 311-320.
70. Brodde, O. E., Vogelsang, M., Broede, A., Michel-Reher, M. et al., Diminished responsiveness of Gs-coupled receptors in severely failing human hearts: no difference in dilated versus ischemic cardiomyopathy. J. Cardiovasc. Pharmacol. 1998, 31, 585-594.
71. Chen, H., Zhang, Y. C., Li, D., Phillips, M. I. et al., Protection against myocardial dysfunction induced by global ischemia-reperfusion by antisense-oligodeoxynucleotides directed at beta(1)-adrenoceptor mRNA. J. Pharmacol. Exp. Ther. 2000, 294, 722-727.
72. He, W., Li, Z.-L., Cui, Y.-L., Yi, B. et al., Effect of icariin on the mRNA expressions of Cbfalpha1, BMP2, BMP4 in rat osteoblasts. Beijing Da Xue Xue Bao 2009, 41, 669-673.
73. Qian, G., Zhang, X., Lu, L., Wu, X. et al., Regulation of Cbfa1 expression by total flavonoids of Herba epimedii. Endocr. J. 2006, 53, 87-94.
74. Yin, X.-X., Chen, Z.-Q., Liu, Z.-J., Ma, Q.-J. et al., Icariine stimulates proliferation and differentiation of human osteoblasts by increasing production of bone morphogenetic protein 2. Chin. Med. J. 2007, 120, 204-210.
75. Yin, X.-X., Chen, Z.-Q., Dang, G.-T., Ma, Q.-J., Effects of Epimedium pubescens icariine on proliferation and differentiation of human osteoblasts. Zhongguo Zhong Yao Za Zhi 2005, 30, 289-291.
76. Hernández, A., Sánchez, E., Soriano, I., Reyes, R. et al., Material-related effects of BMP-2 delivery systems on bone regeneration. Acta. Biomater. 2012, 8, 781-791.
77. Koleganova, N., Piecha, G., Ritz, E., Schmitt, C. P. et al., A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int. 2008, 75, 60-71.
78. Yadava, R. S., Frenzel-McCardell, C. D., Yu, Q., Srinivasan, V. et al., RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat. Genet. 2008, 40, 61-68.
79. Pfeufer, A., van Noord, C., Marciante, K. D., Arking, D. E. et al., Genome-wide association study of PR interval. Nat. Genet. 2010, 42, 153-159.
80. Li, L., Hölscher, C., Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res. Rev. 2007, 56, 384-402.
81. Xin, H., Zhou, F., Liu, T., Li, G.-Y. et al., Icariin ameliorates streptozotocin-induced diabetic retinopathy in vitro and in vivo. Int. J. Mol. Sci. 2012, 13, 866-878.
82. Qi, M.-Y., Kai-Chen, Liu, H.-R., Su, Y.-H. et al., Protective effect of Icariin on the early stage of experimental diabetic nephropathy induced by streptozotocin via modulating transforming growth factor β1 and type IV collagen expression in rats. J. Ethnopharmacol. 2011, 138, 731-736.
83. Cai, W.-J., Huang, J.-H., Zhang, S.-Q., Wu, B. et al., Icariin and its derivative icariside II extend healthspan via insulin/IGF-1 pathway in C. elegans. PLoS One 2011, 6, e28835.
84. Tamatani, M., Ogawa, S., Nuñez, G., Tohyama, M., Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide. Cell Death Differ. 1998, 5, 911-919.
85. Contreras, P. C., Vaught, J. L., Gruner, J. A., Brosnan, C. et al., Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice. Brain Res. 1997, 774, 20-26.
86. Steen, E., Terry, B. M., Rivera, E. J., Cannon, J. L. et al., Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J. Alzheimers Dis. 2005, 7, 63-80.
87. Vaught, J. L., Contreras, P. C., Glicksman, M. A., Neff, N. T., Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease. Ciba Found Symp. 1996, 196, 18-38.
88. Harada, N., Okajima, K., Effects of capsaicin and isoflavone on blood pressure and serum levels of insulin-like growth factor-I in normotensive and hypertensive volunteers with alopecia. Biosci. Biotechnol. Biochem. 2009, 73, 1456-1459.
89. Kajstura, J., Fiordaliso, F., Andreoli, A. M., Li, B. et al., IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001, 50, 1414-1424.
90. Trachtman, H., Maesaka, J., Futterweit, S., Ma, C. et al., The effect of recombinant human insulin-like growth factor-I on chronic puromycin aminonucleoside nephropathy in rats. Pediatr. Res. 1996, 39, 13-19.
91. Vijayan, A., Franklin, S. C., Behrend, T., Hammerman, M. R. et al., Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am. J. Physiol. 1999, 276, R929-R934.
92. Mabuchi, M., Kawamura, I., Takeshita, S., Fushimi, M. et al., Insulin-like growth factor-I enhances choleretic action of FK506 in rats. Transplant. Proc. 2003, 35, 1596-1598.
93. Sanz, S., Pucilowska, J. B., Liu, S., Rodríguez-Ortigosa, C. M. et al., Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury. Gut 2005, 54, 134-141.
94. García-Fernández, M., Castilla-Cortázar, I., Díaz-Sanchez, M., Navarro, I. et al., Antioxidant effects of insulin-like growth factor-I (IGF-I) in rats with advanced liver cirrhosis. BMC Gastroenterol. 2005, 5, 7. doi: 10.1186/1471-230X-5-7.
95. Shen, Y.-C., Chiu, C.-F., Chow, K.-C., Chen, C.-L. et al., Fatal pulmonary fibrosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2. Bone Marrow Transplant. 2004, 34, 609-614.
96. Nian, H., Ma, M., Nian, S., Xu, L. L., Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine 2009, 16, 320-326.
97. Ming, L.-G., Chen, K.-M., Xian, C. J., Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. J. Cell. Physiol. 2013, 228, 513-521.
98. Zhao, J., Ohba, S., Shinkai, M., Chung, U.-I. et al, Icariin induces osteogenic differentiation in vitro in a BMP- and Runx2-dependent manner. Biochem. Biophys. Res. Commun. 2008, 369, 444-448.
99. Xiao, Q., Chen, A., Guo, F., Effects of Icariin on expression of OPN mRNA and type I collagen in rat osteoblasts in vitro. J. Huazhong Univ. Sci. Technol. Med. Sci. 2005, 25, 690-692.
100. Subramanian, V., Krishnamurthy, P., Singh, K., Singh, M., Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H673-H683.
101. Lorena, D., Darby, I. A., Gadeau, A.-P., Leen, L. L. S. et al., Osteopontin expression in normal and fibrotic liver. Altered liver healing in osteopontin-deficient mice. J. Hepatol. 2006, 44, 383-390.
102. Lee, J.-H., Banerjee, A., Ueno, Y., Ramaiah, S. K., Potential relationship between hepatobiliary osteopontin and peroxisome proliferator-activated receptor alpha expression following ethanol-associated hepatic injury in vivo and in vitro. Toxicol. Sci. 2008, 106, 290-299.
103. Dadarkar, S. S., Fonseca, L. C., Mishra, P. B., Lobo, A. S. et al., Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J. Appl. Toxicol. 2011, 31, 117-130.
104. Morris, B. J., Seven sirtuins for seven deadly diseases of aging. Free Radic. Biol. Med. 2012, 56, 133-171.
105. Borradaile, N., Pickering, J., NAD+, sirtuins, and cardiovascular disease. Curr. Pharm. Des. 2009, 15, 110-117.
106. Abdellatif, M., Sirtuins and pyridine nucleotides. Circ. Res. 2012, 111, 642-656.
107. Wang, Y., Xu, C., Liang, Y., Vanhoutte, P. M., SIRT1 in metabolic syndrome: where to target matters. Pharmacol. Ther. 2012, 136, 305-318.
108. Donmez, G., The neurobiology of sirtuins and their role in neurodegeneration. Trends Pharmacol. Sci. 2012, 33, 494-501.
109. Kim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A. et al., SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007, 26, 3169-3179.
110. Shindler, K. S., Ventura, E., Rex, T. S., Elliott, P. et al., SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci. 2007, 48, 3602-3609.
111. Wang, L., Zhang, L., Chen, Z.-B., Wu, J.-Y. et al., Icariin enhances neuronal survival after oxygen and glucose deprivation by increasing SIRT1. Eur. J. Pharmacol. 2009, 609, 40-44.
112. Hsu, C.-P., Zhai, P., Yamamoto, T., Maejima, Y. et al., Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 2010, 122, 2170-2182.
113. Kitada, M., Kume, S., Takeda-Watanabe, A., Kanasaki, K. et al., Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clin. Sci. 2013, 124, 153-164.
114. Sakao, Y., Kato, A., Tsuji, T., Yasuda, H. et al., Cisplatin induces Sirt1 in association with histone deacetylation and increased Werner syndrome protein in the kidney. Clin. Exp. Nephrol. 2011, 15, 363-372.
115. Jung-Hynes, B., Schmit, T. L., Reagan-Shaw, S. R., Siddiqui, I. A. et al., Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J. Pineal. Res. 2011, 50, 140-149.
116. Bruzzone, S., Parenti, M. D., Grozio, A., Ballestrero, A. et al., Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr. Pharm. Des. 2013, 19, 614-623.
117. Kume, S., Haneda, M., Kanasaki, K., Sugimoto, T. et al., SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem. 2007, 282, 151-158.
118. Verdaguer, E., Junyent, F., Folch, J., Beas-Zarate, C. et al., Aging biology: a new frontier for drug discovery. Expert Opin. Drug Discov. 2012, 7, 217-229.
119. Over, B., Wetzel, S., Grütter, C., Nakai, Y. et al., Natural-product-derived fragments for fragment-based ligand discovery. Nat. Chem. 2012, 5, 21-28.
120. Azorín-Ortuño, M., Yáñez-Gascón, M. J., González-Sarrías, A., Larrosa, M. et al., Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention. J. Nutr. Biochem. 2012, 23, 829-837.
121. Baur, J. A., Ungvari, Z., Minor, R. K., Le Couteur, D. G., Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 2012, 11, 443-461.
122. Vauzour, D., Dietary polyphenols as modulators of brain functions: biological actions and molecular mechanisms underpinning their beneficial effects. Oxid. Med. Cell Longev. 2012, 2012, 914273. doi:10.1155/2012/914273.
123. Wakade, C., Khan, M. M., De Sevilla, L. M., Zhang, Q.-G. et al., Tamoxifen neuroprotection in cerebral ischemia involves attenuation of kinase activation and superoxide production and potentiation of mitochondrial superoxide dismutase. Endocrinology 2008, 149, 367-379.
124. Song, Y. S., Narasimhan, P., Kim, G. S., Jung, J. E. et al., The role of Akt signaling in oxidative stress mediates NF-kappaB activation in mild transient focal cerebral ischemia. J. Cereb. Blood Flow Metab. 2008, 28, 1917-1926.
125. Tureyen, K., Kapadia, R., Bowen, K. K., Satriotomo, I. et al., Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J. Neurochem. 2007, 101, 41-56.
126. Nagayama, M., Zhang, F., Iadecola, C., Delayed treatment with aminoguanidine decreases focal cerebral ischemic damage and enhances neurologic recovery in rats. J. Cereb. Blood Flow Metab. 1998, 18, 1107-1113.
127. Bullock, J. J., Mehta, S. L., Lin, Y., Lolla, P. et al., Hyperglycemia-enhanced ischemic brain damage in mutant manganese SOD mice is associated with suppression of HIF-1alpha. Neurosci. Lett. 2009, 456, 89-92.
128. Maier, C. M., Hsieh, L., Yu, F., Bracci, P. et al., Matrix metalloproteinase-9 and myeloperoxidase expression: quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke 2004, 35, 1169-1174.
129. Alies, B., Eury, H., Bijani, C., Rechignat, L. et al., pH-dependent Cu(II) coordination to amyloid-β peptide: impact of sequence alterations, including the H6R and D7N familial mutations. Inorg. Chem. 2011, 50, 11192-11201.
130. Watt, A. D., Perez, K. A., Faux, N. G., Pike, K. E. et al., Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease. J. Alzheimers Dis. 2011, 24, 47-59.
131. Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C. et al., Aβ40 oligomers identified as a potential biomarker for the diagnosis of alzheimer's disease. PLoS One 2010, 5, e15725.
132. Marino, T., Russo, N., Toscano, M., Pavelka, M., On the metal ion (Zn(2+), Cu(2+)) coordination with beta-amyloid peptide: DFT computational study. Interdiscip. Sci. 2010, 2, 57-69.
133. Marwarha, G., Dasari, B., Prasanthi, J. R. P., Schommer, J. et al., Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J. Alzheimers Dis. 2010, 19, 1007-1019.
134. Di Fede, G., Catania, M., Morbin, M., Rossi, G. et al., A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323, 1473-1477.
135. Lin, R., Chen, X., Li, W., Han, Y. et al., Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci. Lett. 2008, 440, 344-347.
136. Agnati, L. F., Genedani, S., Leo, G., Forni, A. et al., Abeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease. J. Neural Transm. 2007, 114, 21-31.
137. Kong, G. K.-W., Adams, J. J., Harris, H. H., Boas, J. F. et al., Structural studies of the Alzheimer's amyloid precursor protein copper-binding domain reveal how it binds copper ions. J. Mol. Biol. 2007, 367, 148-161.
138. Lahiri, D. K., Maloney, B., Basha, M. R., Ge, Y. W. et al., How and when environmental agents and dietary factors affect the course of Alzheimer's disease: the 'LEARn' model (latent early-life associated regulation) may explain the triggering of AD. Curr. Alzheimer Res. 2007, 4, 219-228.
139. Atamna, H., Boyle, K., Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2006, 103, 3381-3386.
140. Miller, L. M., Wang, Q., Telivala, T. P., Smith, R. J. et al., Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 2006, 155, 30-37.
141. Syme, C. D., Viles, J. H., Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease. Biochim. Biophys. Acta. 2006, 1764, 246-256.
142. Costello, D. A., O'Leary, D. M., Herron, C. E., Agonists of peroxisome proliferator-activated receptor-gamma attenuate the Abeta-mediated impairment of LTP in the hippocampus in vitro. Neuropharmacology 2005, 49, 359-366.
143. Nelson, T. J., Alkon, D. L., Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J. Biol. Chem. 2005, 280, 7377-7387.
144. Santos, M. J., Quintanilla, R. A., Toro, A., Grandy, R. et al., Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J. Biol. Chem. 2005, 280, 41057-41068.
145. Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J. et al., Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280, 5892-5901.
146. Opazo, C., Barría, M. I., Ruiz, F. H., Inestrosa, N. C., Copper reduction by copper binding proteins and its relation to neurodegenerative diseases. Biometals 2003, 16, 91-98.
147. Tatton, W., Chen, D., Chalmers-Redman, R., Wheeler, L. et al., Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv. Ophthalmol. 2003, 48(Suppl 1), S25-S37.
148. Zhong, P., Gu, Z., Wang, X., Jiang, H. et al., Impaired modulation of GABAergic transmission by muscarinic receptors in a mouse transgenic model of Alzheimer's disease. J. Biol. Chem. 2003, 278, 26888-26896.
149. Opazo, C., Huang, X., Cherny, R. A., Moir, R. D. et al., Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J. Biol. Chem. 2002, 277, 40302-40308.
150. Behl, C., Davis, J., Cole, G. M., Schubert, D., Vitamin E protects nerve cells from amyloid beta protein toxicity. Biochem. Biophys. Res. Commun. 1992, 186, 944-950.
151. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N. et al., Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. USA 2006, 103, 443-448.
152. Akomolafe, A., Lunetta, K. L., Erlich, P. M., Cupples, L. A. et al., Genetic association between endothelial nitric oxide synthase and Alzheimer disease. Clin. Genet. 2006, 70, 49-56.
153. Dahiyat, M., Cumming, A., Harrington, C., Wischik, C. et al., Association between Alzheimer's disease and the NOS3 gene. Ann. Neurol. 1999, 46, 664-667.
154. Reed, T. T., Pierce, W. M., Markesbery, W. R., Butterfield, D. A., Proteomic identification of HNE-bound proteins in early Alzheimer disease: insights into the role of lipid peroxidation in the progression of AD. Brain Res. 2009, 1274, 66-76.
155. Bivalacqua, T. J., Deng, W., Kendirci, M., Usta, M. F. et al., Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H1278-H1290.
156. Rajasekaran, M., Kasyan, A., Jain, A., Kim, S.-W. et al., Altered growth factor expression in the aging penis: the Brown-Norway rat model. J. Androl. 2002, 23, 393-399.
157. Deng, F.-Y., Liu, Y.-Z., Li, L.-M., Jiang, C. et al., Proteomic analysis of circulating monocytes in Chinese premenopausal females with extremely discordant bone mineral density. Proteomics 2008, 8, 4259-4272.
158. Ota, H., Takeyama, H., Nakayama, H., Katoh, T. et al., SNP detection in transforming growth factor-beta1 gene using bacterial magnetic particles. Biosens. Bioelectron. 2003, 18, 683-687.
159. Sharma, S., Ying, J., Razeghi, P., Stepkowski, S., Atrophic remodeling of the transplanted rat heart. Cardiology 2006, 105, 128-136.
160. Zhou, M., Wang, S., Zhao, A., Wang, K. et al., Transcriptomic and metabonomic profiling reveal synergistic effects of quercetin and resveratrol supplementation in high fat diet fed mice. J. Proteome. Res. 2012, 11, 4961-4971.